SLDB Jun 2024 10.000 put
| Previous Close | 1.6500 |
| Open | 1.6500 |
| Bid | 0.1000 |
| Ask | 4.6000 |
| Strike | 10.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 1.6500 - 1.6500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 20 |
Simply Wall St.We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
GlobeNewswireSolid Biosciences Provides First Quarter 2024 Business Update and Financial Results
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 — — Company entered into non-exclusive licensing agreement for use of its proprietary, muscle-targeted AAV-SLB101 capsid — — Company ends first quarter 2024 with approximately $206.1 million in cash and investments.Solid has anticipated cash runway into 2026 — CHARLESTOWN, Mass., May 15, 2024 (GLOBE NEWSWIRE)
- GlobeNewswire
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
— Presentations to highlight AAV manufacturing and purification improvements, vector biology updates,and a comprehensive non-clinical data overview of the company’s lead SGT-003 program — CHARLESTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present an oral presentation and six posters and at the American Society of Gene and Cell Therapy (ASGCT) 2024 A
